6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Company News

Vivus receives CHMP negative opinion on Qsiva

As expected, EMA's CHMP recommended against approval of an MAA for obesity drug Qsiva phentermine/topiramate from Vivus Inc. (NASDAQ:VVUS). Vivus said the committee expressed concerns over the potential cardiovascular and...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >